List view / Grid view
Drug discovery now costs 100 times more per FDA-approved drug than in 1950, despite vast advances in biology and computing. The core problem is the collapse of predictive validity in preclinical models, which sits at the heart of pharma’s productivity paradox.
New research has demonstrated how tiny tweaks in a DNA-sensing enzyme may hold the key to the naked mole-rat’s extraordinary lifespan – offering insights that could one day inform therapies for aging and age-related diseases.
Researchers have refined a cutting-edge DNA sequencing tool that reveals how mutations accumulate in healthy tissues as we age, offering insights into the earliest stages of cancer development.
A newly discovered antibody, 04_A06, has shown unprecedented effectiveness against HIV, neutralising 98.5 percent of tested strains and permanently suppressing the virus in humanised mice.
A new study has demonstrated that sweet-sensing taste cells, protected by the protein c-Kit, survive nerve injury and drive the regeneration of taste buds.
Korean researchers have discovered that oral bacteria in the gut may contribute to Parkinson’s disease – highlighting a potential new target for treatment.
As cancer drugs continue to fail in translation, researchers are turning back to patient-derived xenograft (PDX) models – this time with better science. Could they be the missing link between the lab and the clinic?
Virginia Tech computer scientists have created a new AI tool, ProRNA3D-single, that can generate 3D models of how viral RNA binds to human proteins – a development that could speed up drug discovery.
Scientists at Tufts University have developed an AI tool that demonstrates how tuberculosis drugs kill bacteria – an advancement that could speed-up the discovery of shorter, more effective treatments.
UCLA scientists have created the first detailed map of how the ovarian reserve forms in primates, offering new insights – and potential new treatments – for infertility, polycystic ovary syndrome (PCOS) and hormone-related conditions.
Researchers at the University of Waterloo have developed a modified bacterial virus that can deliver gene therapies cheaper and more efficiently – moving us closer toward personalised, affordable genetic medicine.
Porosome Therapeutics has announced new advancements in Alzheimer’s treatment – presenting therapies that restore neuronal function, reduce Tau protein levels and reverse disease pathology in human brain organoids.
Researchers have discovered that the protein intersectin plays a crucial role in organising synaptic vesicles – enabling direct communication essential for learning and memory.
Scientists have discovered that cancer cells generate an instant burst of energy when physically squeezed, helping them repair DNA damage and survive harsh environments. This discovery means that therapies targeting this new survival mechanism could be developed.
As radioligand therapy continues to show promise, its application in solid tumours remains limited by long-standing biological challenges. In this interview, Julien Torgue, CSO at Orano Med, discusses a new collaborative platform – Radio-DARPins – and how it could help overcome key barriers to clinical progress.
